Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Emerging therapeutic strategies in breast cancer (Oct 2026)
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles
  • Search Articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling
Andreas Sturm, Jugoh Itoh, James W. Jacobberger, Claudio Fiocchi
Andreas Sturm, Jugoh Itoh, James W. Jacobberger, Claudio Fiocchi
View: Text | PDF
Article Immunology

p53 negatively regulates intestinal immunity by delaying mucosal T cell cycling

  • Text
  • PDF
Abstract

To mount an effective immune response, T cells must divide in response to antigen contact. To maintain tolerance, mucosal lamina propria T cells (LPTs) may adapt their cycling to an antigen-rich gut stimulatory environment. Here, we compared the cell cycle kinetics of LPTs and peripheral blood T cells (PBTs) before and after CD3- and CD2-mediated activation. While CD3-activated naive (CD45RA+) and memory (CD45RO+) PBTs peaked in the S and G2/M phase at 2–3 days, CD3-activated LPTs peaked at 4–6 days. In contrast, CD2 activation induced modest PBT but vigorous LPT cycling. The doubling time of CD3-activated PBTs was 1 day, while that of CD3- or CD2-activated LPTs was 2 days. LPTs failed to upregulate cyclin-dependent kinase 4 and cyclin D3, but Rb phosphorylation and cyclin A and B1 upregulation were induced by CD2 engagement. The extents of clonal expansion in LPT and PBT were comparable, indicating that LPTs’ slow replication delays but does not hinder cell division. CD2-activated LPTs displayed a striking upregulation of p53, whose blockade by antisense oligonucleotides accelerated their S phase transit time to that of CD3-activated PBTs. By slowing LPT cycling, p53 may act as a negative regulator of mucosal immunity, promoting immunological tolerance by preventing excessive T cell replication.

Authors

Andreas Sturm, Jugoh Itoh, James W. Jacobberger, Claudio Fiocchi

×

Figure 3

Options: View larger image (or click on image) Download as PowerPoint
(a) Different levels of cell cycle promoters in PBTs and LPTs. Immunoblo...
(a) Different levels of cell cycle promoters in PBTs and LPTs. Immunoblot analysis shows that upregulation of CDK4 and cyclin D3 is only detected in CD3-activated PBTs, but not in PBTs or LPTs activated through the CD2 and CD3 pathways. Rb phosphorylation (pRb) was minimal in CD2-activated PBTs but markedly increased after CD3 activation, whereas, in LPTs, engagement of either the CD2 or CD3 pathway led to strong Rb phosphorylation. Strong upregulation of cyclin A in PBTs was induced by CD3 activation, whereas CD2 activation was required for an equally strong upregulation in LPTs. (b) Different levels of cell cycle inhibitors in PBTs and LPTs. The level of p21 varies little in unstimulated and stimulated PBTs and LPTs, except for a moderate increase in CD3-activated PBTs. Levels of the inhibitor p27 are downregulated in CD3-stimulated PBTs but not CD3-stimulated LPTs. Activation through the CD2 pathway induces a striking upregulation of p53 in LPTs but only a moderate increase in PBTs, whereas CD3 stimulation induces a lower and comparable p53 upregulation in PBTs and LPTs. Freshly isolated PBTs and LPTs were cultured in the absence and presence of CD3 or CD2 mAb for 3 days, after which expression of cell cycle inhibitors was assessed by Western blotting. Each bar represents the densitometry units of individual protein bands normalized to their own GAPDH. Each panel is representative of five to seven different experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts